A Brief Report of a Phase II trial Evaluating Efficacy and Safety of Hypomethylating Agent Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer
Authors:
- 21 March 2023
- journal article
- research article
- Published by Elsevier in Clinical Lung Cancer
- Vol. 24 (4) , 347-352
Abstract
No abstract availableKeywords
Funding Information
- Astex Pharmaceuticals
This publication has 14 references indexed in Scilit:
- First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung CancerNew England Journal of Medicine, 2018
- ATLANTIS: A Phase III Study of Lurbinectedin/Doxorubicin Versus Topotecan or Cyclophosphamide/Doxorubicin/Vincristine in Patients with Small-Cell Lung Cancer Who Have Failed one Prior Platinum-Containing LineFuture Oncology, 2018
- Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 AxisCancer Cell, 2017
- A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLCCancer Cell, 2015
- DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2Oncogene, 2015
- A Randomized Phase III Study of Single-Agent Amrubicin Vs. Carboplatin/Etoposide in Elderly Patients With Extensive-Disease Small-Cell Lung CancerClinical Lung Cancer, 2014
- Genomic Deregulation of the E2F/Rb Pathway Leads to Activation of the Oncogene EZH2 in Small Cell Lung CancerPLOS ONE, 2013
- EZH2 Promotes E2F-Driven SCLC Tumorigenesis through Modulation of Apoptosis and Cell-Cycle RegulationJournal of Thoracic Oncology, 2013
- Immunomodulatory activity of SGI-110, a 5-aza-2′-deoxycytidine-containing demethylating dinucleotideCancer Immunology, Immunotherapy, 2012
- Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCISTJournal of Cancer, 2010